

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable

standards of care

PROTOCOL CODE: UBRAJKAD

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment

DOCTOR'S ORDERS Htcm Wtkg B	SAm²
REMINDER: Please ensure drug allergies and previous bleomycin are documented or	n the Allergy & Alert Form
DATE: To be given: Cycle #:	
Date of Previous Cycle:	
☐ Delay Treatment week(s) ☐ CBC & Diff, Platelets day of treatment May proceed with doses as written if within 96 hours ANC greater than or equal to 1.0 x 10°/L and Platelets greater than or equal to 75 x 10°/L Dose modification for: ☐ Hematology ☐ Renal Function ☐ Other Toxicity Proceed with treatment based on blood work from	
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm	
□ prochlorperazine 10 mg PO or □ metoclopramide 10 to 20 mg PO prior to treatment□ Other:	
Have Hypersensitivity Reaction Tray and Protocol Available	
trastuzumab emtansine (KADCYLA) 3.6 mg/kg xkg =mg □ Dose Modification: mg/kg xkg = mg IV in 250 mL NS over 1 h 30 min using a 0.2 micron in-line filter. Observe for 1 hour 30 minutes post infusion. If no infusion reaction observed in Cycle 1, may administer subsequent cycles over 30 minutes, observe for 30 minutes post-infusion. Observation period not required after 3 treatments with no reaction.	
RETURN APPOINTMENT ORDERS	
Return in three weeks for Doctor and Cycle Last Cycle. Return inweeks.	
CBC & Diff, platelets, bilirubin, ALT, alkaline phosphatase, LDH, GGT prior to each cycle MUGA Scan or Echocardiogram every	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: